Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies Initially Diagnosed as Immune Thrombocytopenia and Reclassified After 10 Years: Diagnostic Pitfall Revealed by a Family History.

Internal medicine (Tokyo, Japan)·2026
Same author

Continuous Glucose Monitoring for Detecting Hypoglycemia During Maintenance Therapy for Acute Lymphoblastic Leukemia.

Pediatrics international : official journal of the Japan Pediatric Society·2026
Same author

A potent and selective PHOX2B promoter-driven oncolytic adenovirus for targeted neuroblastoma therapy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026
Same author

mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac).

Molecular therapy. Oncology·2026
Same author

Trends, Demographic Characteristics, and Seasonal Patterns of Nonoperative and Operative Reduction for Intussusception: A Preliminary Nationwide Claims-Based Analysis from 2014 to 2023 in Japan.

Internal medicine (Tokyo, Japan)·2026

相关实验视频

Updated: Jun 18, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

[用于固体瘤的收养细胞疗法]

Kenichi Sakamoto1, Shigeki Yagyu2

  • 1Department of Pediatrics, Shinshu University School of Medicine.

[Rinsho ketsueki] The Japanese journal of clinical hematology
|August 4, 2024
PubMed
概括

采用细胞疗法 (ACT) 对固体瘤有希望,但抗原识别和瘤微环境相互作用等挑战需要解决. 本综述探讨了当前的数据和未来的战略,以推动ACT在固体瘤中的进展.

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法已经改变了耐药/复发性 (R/R) 血液恶性瘤的治疗.
  • 六种CAR T细胞产品已被批准用于B细胞瘤和多发性髓瘤.
  • 采用细胞疗法 (ACT) 在固体瘤中面临重大障碍.

研究的目的:

  • 对实体瘤中ACT的临床试验数据进行审查.
  • 阐明目前针对固体瘤的ACT开发的现状.
  • 在实体瘤中概述ACT的轨迹和整合方法.

主要方法:

  • 对实体瘤的ACT现有临床试验数据的审查.
  • 对实体瘤的ACT挑战的分析.
  • 探索克服瘤微环境的策略.

主要成果:

  • 固体瘤的ACT因缺乏瘤特异性抗原而受到挑战.
  • 不有效的T细胞贩运和透到瘤微环境是关键问题.
  • 瘤环境中的免疫抑制信号诱导T细胞功能障碍.

结论:

关键词:
收养细胞疗法采用细胞疗法.化学抗原受体的化学抗原受体固体瘤是一个固体瘤.T细胞受体受体的 T 细胞受体.

更多相关视频

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K

相关实验视频

Last Updated: Jun 18, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K
  • ACT对固体瘤有潜力,但需要克服重要的生物障碍.
  • 未来的战略必须解决抗原向,T细胞贩运和免疫抑制瘤微环境.
  • 综合性方法对于推动ACT在固体瘤治疗方面至关重要.